[go: up one dir, main page]

WO1998039362A1 - Immunoglobulines cytotoxiques provenant de mammiferes - Google Patents

Immunoglobulines cytotoxiques provenant de mammiferes Download PDF

Info

Publication number
WO1998039362A1
WO1998039362A1 PCT/EP1998/001112 EP9801112W WO9839362A1 WO 1998039362 A1 WO1998039362 A1 WO 1998039362A1 EP 9801112 W EP9801112 W EP 9801112W WO 9839362 A1 WO9839362 A1 WO 9839362A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulins
cytotoxic
igm
mammals
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/001112
Other languages
English (en)
Inventor
Alberto Bartorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VANDER WAY Ltd
Original Assignee
VANDER WAY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VANDER WAY Ltd filed Critical VANDER WAY Ltd
Priority to AU63999/98A priority Critical patent/AU6399998A/en
Publication of WO1998039362A1 publication Critical patent/WO1998039362A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to i munoglobulins of the M type (IgM) and immunoglobulins of the G type (IgG) from mammals, having cytotoxic activity against " human tumour cells.
  • the invention further relates to the use of said IgM and IgG for the preparation of antitumour medicaments .
  • IgG immunoglobulins
  • IgM immunoglobulins responsible for the early immune response.
  • IgG have been already used in the therapy or in the specific or aspecific prevention of infectious diseases, such as chickenpox, pertussis, hepatitis, tetanus, rubella, measles etc..
  • Ig and IgM isolated from serum of healthy mammals have marked cytotoxic activity against human tumour cells.
  • the main cytotoxicity percentages are related to IgM, but IgG of the selected animals have interesting cytotoxic properties as well.
  • antitumour cytotoxic IgM and IgG can be extracted from any mammals, in particular from bovine ⁇ , equines, swine, rabbits.
  • Preferred sources are swine, in that the sera of all the tested pigs turned out to be cytotoxic, whereas in the other species a percentage of positive (cytotoxic) sera ranging from
  • the serum of the animals which turned out to be positive can then be subjected to conventional treatments for the separation and the purification of the IgM and IgG fractions.
  • the serum after decomplementation at 56 ⁇ C for 30 minutes, is subjected to gel filtration on a TSK SW 3000 preparative column (Toso Haas) which is eluted with 0.3 M PBS pH 7 under a pressure of 250 p.s.i. and with a flow of 2 ml/min. , to obtain a first fraction, mainly consisting of IgM, and a second fraction, mainly consisting of IgG.
  • IgG can be further purified passing them through a G protein column (Hi
  • IgM from the first fraction can be further purified as well by conventional methods, for example by affinity chromatography using anti-IGM antibodies.
  • the cytotoxicity of the serum is maintained in the two IgM and IgG fractions, the first having variable values higher than 60%, the second having lower values of about 30 to 40%.
  • the cytotoxic IgM and IgG fractions injected to nude mice or to tumor-bearing rats (HT-29), cause the tumor growth to be stopped and regressed.
  • the immunoglobulins Ig and IgM of the invention will be administered to patients suffering from tumors, in the form of pharmaceutical formulations suitable for the parenteral, preferably subcutaneous or intramuscular, administrations .
  • the doses depend of course on the conditions of the patient (weight, sex and age) and the severity of the pathology, but they will range from about 10 mg to about 200 mg/day.
  • the treatment can be optionally carried out in combination with other conventional immunotherapeutic or chemotherapeutic treatments.
  • Apirogenic sterile water 1 ml .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention a pour objet des immunoglobulines naturelles M et G, extraites de mammifères, en particulier de lapins et de porcs. Ces immunoglobulines exercent une action cytotoxique in vitro et in vivo contre les cellules tumorales.
PCT/EP1998/001112 1997-03-04 1998-02-27 Immunoglobulines cytotoxiques provenant de mammiferes Ceased WO1998039362A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63999/98A AU6399998A (en) 1997-03-04 1998-02-27 Cytotoxic immunoglobulins from mammals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI000474A IT1290018B1 (it) 1997-03-04 1997-03-04 Immunoglobuline citotossiche da mammiferi
ITMI97A000474 1997-03-04

Publications (1)

Publication Number Publication Date
WO1998039362A1 true WO1998039362A1 (fr) 1998-09-11

Family

ID=11376274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001112 Ceased WO1998039362A1 (fr) 1997-03-04 1998-02-27 Immunoglobulines cytotoxiques provenant de mammiferes

Country Status (3)

Country Link
AU (1) AU6399998A (fr)
IT (1) IT1290018B1 (fr)
WO (1) WO1998039362A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038439A3 (fr) * 2001-11-02 2003-09-25 Megamedics Gmbh Identification fonctionnelle de cibles sur des tissus et cellules
WO2015155217A1 (fr) * 2014-04-09 2015-10-15 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Procédé de purification d'anticorps igm cytotoxiques naturels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268973A2 (fr) * 1986-11-27 1988-06-01 Biotest Pharma GmbH Procédé de production d'une préparation d'immunoglobuline G intraveineuse, stable et libre de virus
EP0412486A1 (fr) * 1989-08-06 1991-02-13 Yeda Research And Development Company, Ltd. Anticorps contre la protéine de liaison I au facteur de nécrose tumorale (TNF) et leurs fragments F(ab)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268973A2 (fr) * 1986-11-27 1988-06-01 Biotest Pharma GmbH Procédé de production d'une préparation d'immunoglobuline G intraveineuse, stable et libre de virus
EP0412486A1 (fr) * 1989-08-06 1991-02-13 Yeda Research And Development Company, Ltd. Anticorps contre la protéine de liaison I au facteur de nécrose tumorale (TNF) et leurs fragments F(ab)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARTORELLI A. ET AL: "Antibody-dependent cytotoxic activity on human cancer cells expressing UK 114 tumor membrane antigen", INT. J. ONCOLOGY, vol. 8, no. 3, 1996, pages 543 - 548, XP002067969 *
BOHN J. ET AL.: "Binding of natural human IgM auto-antibodies to human tumor cell lines and stimulated normal T lymphocytes", IMMUNOL. LETT., vol. 30, no. 2, 1994, pages 187 - 194, XP002067970 *
BUSSOLATI G. ET AL.: "Cytolytic and tumor inhibitory antibodies against UK114 protein in the sera of cancer patients", INT. J. ONCOLOGY, vol. 10, no. 4, April 1997 (1997-04-01), pages 779 - 785, XP002067972 *
HERLYN D. ET AL.: "Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells", CELL. IMMUNOL, vol. 92, no. 1, 1985, pages 105 - 114, XP002067971 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038439A3 (fr) * 2001-11-02 2003-09-25 Megamedics Gmbh Identification fonctionnelle de cibles sur des tissus et cellules
WO2015155217A1 (fr) * 2014-04-09 2015-10-15 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Procédé de purification d'anticorps igm cytotoxiques naturels

Also Published As

Publication number Publication date
AU6399998A (en) 1998-09-22
ITMI970474A1 (it) 1998-09-04
IT1290018B1 (it) 1998-10-19

Similar Documents

Publication Publication Date Title
CA2146647C (fr) Traitement d'affections auto-immunes et inflammatoires
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
Herlyn et al. Anti-idiotype immunization of cancer patients: modulation of the immune response.
JP2577868B2 (ja) ヒトγ−インターフェロン特異的受容体蛋白質に対する抗体
US8444974B2 (en) Use of antibodies for the vaccination against cancer
JPH10505819A (ja) 腫瘍の治療及び予防のための自己抗体の使用方法
RU2607022C2 (ru) Способы и композиции для лечения волчанки
Wilson Study of the immunopathogenesis of tubulointerstitial nephritis using model systems
JP2852705B2 (ja) 自己免疫疾患の治療
EP0525570A2 (fr) Anticorps anti-idiotypiques imitant le TNF
Dayer et al. Cartilage proteoglycan‐induced arthritis in BALB/c mice. Antibodies that recognize human and mouse cartilage proteoglycan and can cause depletion of cartilage proteoglycan with little or no synovitis
Ebersole et al. The effect of neonatal thymectomy on the level of salivary and serum immunoglobulins in rats
JPH04506666A (ja) ワクチンアジュバントとしてのｌｆａ―３
WO1998039362A1 (fr) Immunoglobulines cytotoxiques provenant de mammiferes
Marusić-Galesić et al. Cellular immune response to the antigen administered as an immune complex
Marusić-Galesić et al. Cellular immune response to the antigen administered as an immune complex in vivo
EP1367393A1 (fr) Procédé d'utilisation de la voie CD 163 pour la modulation d'une réponse Immunitaire
Petty et al. Immunity to ocular and collagen antigens in childhood arthritis and uveitis
Koyama et al. Effect of chemical modification of antigen on characteristics of immune complexes and their glomerular localization in the murine renal tissues
AU2002242447B2 (en) Use of polyclonal immunoglobulins
Feintzeig et al. Antibody, antigen, and glomerular capillary wall charge interactions: influence of antigen location on in situ immune complex formation
EP1618890B1 (fr) Utilisation d'anticorps en très faibles doses pour vaccination contre le cancer
Sivolapenko et al. Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies
Arlen et al. Monoclonal antibodies and their role in modulation of the immune response
WO2025051309A1 (fr) Anticorps bispécifiques liant le cd3 et le ganglioside ngcgm3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538125

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA